Skip to main content
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1981 Sep;45(3):576–582.

Interferon production of vitro by leucocytes from patients with systemic lupus erythematosus and rheumatoid arthritis.

P A Neighbour, A I Grayzel
PMCID: PMC1537416  PMID: 6175456

Abstract

The production of interferons (IFN) by peripheral blood leucocytes from normal donors an patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) has been investigated in response to several IFN inducers in vitro. Whereas IFN responses of RA donors did not differ significantly from the normal group, those of SLE patients were significantly reduced, and many of these patients failed to respond to all. Patients with active or acute SLE responded significantly less well than those with inactive disease. There was no apparent effect of steroid therapy on the IFN responses of either SLE or RA patients. These data may indicate a basic immunological defect of the circulating leucocytes of SLE patients, which may be responsible for some of the in vitro lymphocyte anomalies reported for this disease.

Full text

PDF
576

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón-Segovia D., Ruiz-Gómez J., Fishbein E., Bustamante M. E. Interferon production by lymphocytes from patients with systemic lupus erythematosus. Arthritis Rheum. 1974 Sep-Oct;17(5):590–592. doi: 10.1002/art.1780170513. [DOI] [PubMed] [Google Scholar]
  2. Baum J., Ziff M. Decreased 19S antibody response to bacterial antigens in systemic lupus erythematosus. J Clin Invest. 1969 Apr;48(4):758–767. doi: 10.1172/JCI106033. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bresnihan B., Jasin H. E. Suppressor function of peripheral blood mononuclear cells in normal individuals and in patients with systemic lupus erythematosus. J Clin Invest. 1977 Jan;59(1):106–116. doi: 10.1172/JCI108607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Epstein L. B. Mitogen and antigen induction of interferon in vitro and in vivo. Tex Rep Biol Med. 1977;35:42–56. [PubMed] [Google Scholar]
  5. Fauci A. S., Steinberg A. D., Haynes B. F., Whalen G. Immunoregulatory aberrations in systemic lupus erythematosus. J Immunol. 1978 Oct;121(4):1473–1479. [PubMed] [Google Scholar]
  6. Hoffman T. Natural killer funciton in systemic lupus erythematosus. Arthritis Rheum. 1980 Jan;23(1):30–35. doi: 10.1002/art.1780230106. [DOI] [PubMed] [Google Scholar]
  7. Hooks J. J., Moutsopoulos H. M., Geis S. A., Stahl N. I., Decker J. L., Notkins A. L. Immune interferon in the circulation of patients with autoimmune disease. N Engl J Med. 1979 Jul 5;301(1):5–8. doi: 10.1056/NEJM197907053010102. [DOI] [PubMed] [Google Scholar]
  8. Kadish A. S., Tansey F. A., Yu G. S., Doyle A. T., Bloom B. R. Interferon as a mediator of human lymphocyte suppression. J Exp Med. 1980 Mar 1;151(3):637–650. doi: 10.1084/jem.151.3.637. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lee S. H., Ozere R. L., Van Rooyen C. E. Interferon production by human leucocytes in vitro. Reduced levels in lymphatic leukemia. Proc Soc Exp Biol Med. 1966 May;122(1):32–39. doi: 10.3181/00379727-122-31043. [DOI] [PubMed] [Google Scholar]
  10. Moretta A., Mingari M. C., Santoli D., Perlmann P., Moretta L. Human T-lymphocyte subpopulations: alterations in systemic lupus erythematosus. Scand J Immunol. 1979;10(3):223–228. doi: 10.1111/j.1365-3083.1979.tb01343.x. [DOI] [PubMed] [Google Scholar]
  11. Neighbour P. A., Bloom B. R. Absence of virus-induced lymphocyte suppression and interferon production in multiple sclerosis. Proc Natl Acad Sci U S A. 1979 Jan;76(1):476–480. doi: 10.1073/pnas.76.1.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Pidot A. L., Maurer L. H., McIntyre O. R. Leukocyte interferon production, RNA synthesis, and PHA response in patients with infectious mononucleosis. Blood. 1973 Aug;42(2):175–185. [PubMed] [Google Scholar]
  13. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  14. Rassiga-Pidot A. L., McIntyre O. R. In vitro leukocyte interferon production in patients with Hodgkin's disease. Cancer Res. 1974 Nov;34(11):2995–3002. [PubMed] [Google Scholar]
  15. Rosenthal C. J., Franklin E. C. Depression of cellular-mediated immunity in systemic lupus erythematosus. relation to disease activity. Arthritis Rheum. 1975 May-Jun;18(3):207–217. doi: 10.1002/art.1780180303. [DOI] [PubMed] [Google Scholar]
  16. Santoli D., Koprowski H. Mechanisms of activation of human natural killer cells against tumor and virus-infected cells. Immunol Rev. 1979;44:125–163. doi: 10.1111/j.1600-065x.1979.tb00269.x. [DOI] [PubMed] [Google Scholar]
  17. Sonnenfeld G., Mandel A. D., Merigan T. C. Time and dosage dependence of immunoenhancement by murine type II interferon preparations. Cell Immunol. 1978 Oct;40(2):285–293. doi: 10.1016/0008-8749(78)90336-2. [DOI] [PubMed] [Google Scholar]
  18. Trinchieri G., Santoli D. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J Exp Med. 1978 May 1;147(5):1314–1333. doi: 10.1084/jem.147.5.1314. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Trinchieri G., Santoli D., Dee R. R., Knowles B. B. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the anti-viral activity as interferon and characterization of the human effector lymphocyte subpopulation. J Exp Med. 1978 May 1;147(5):1299–1313. doi: 10.1084/jem.147.5.1299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Yamaguchi T., Handa K., Shimizu Y., Abo T., Kumagai K. Target cells for interferon production in human leukocytes stimulated by sendai virus. J Immunol. 1977 Jun;118(6):1931–1935. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES